A tie-up between a Chinese research institute and tech company said on Monday that it aims to implant its brain chip into 13 ...

In the past, these unforeseen consequences have stopped some effective forms from continuing in human trials. This has led ...

The Trump administration's cuts to the National Institutes of Health has some worried about stalls in research and medicine.

- CYT-108 is a recombinant protease inhibitor therapy with potential disease-modifying effects - JUPITER, Fla., April 1, 2025 /PRNewswire/ -- Cytonics, an early-stage biopharmaceutical company ...

The world's first baby conceived through robot-controlled fertilization has been born, researchers say. The boy was born to a ...

Katie Doble is on her computer looking to connect with anyone who might share her fight for clinical research knowing her ...

In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...

The HFpEF Summit is a biannual, two-day meeting bringing together internationally recognized leaders in the clinical, biological, and translational study of HFpEF. This summit focused on the latest ...

After decades of trial and error, a promising new target for Lyme disease vaccine is emerging—the Lyme bacterial protein CspZ, which the bacteria use to evade detection from the body’s immune system.

"An appealing feature of [intermittent fasting] is that dieters do not have to focus on counting calories and restricting ...

A Wuhan-based biopharmaceutical company developed technology to synthesize human serum albumin (HSA) from rice, offering a ...

today announced that the last patient has completed their last visit in the Company's first-in-human clinical trial of CYT-108, a novel recombinant protein variant of an endogenous, broad-spectrum ...